Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
The Pharma Data
NOVEMBER 9, 2020
Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. Source: Novavax, Inc. .
Let's personalize your content